Safety and Activity of Sorafenib in Different Histotypes of Advanced Renal Cell Carcinoma

Ronald Bukowski, David Cella, Kathleen Gondek, Bernard Escudier, None, Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. American Journal of Clinical Oncology. ,vol. 30, pp. 220- 227 ,(2007) , 10.1097/01.COC.0000258732.80710.05

Bernard Escudier, Tim Eisen, Walter M Stadler, Cezary Szczylik, Stéphane Oudard, Michael Siebels, Sylvie Negrier, Christine Chevreau, Ewa Solska, Apurva A Desai, Frédéric Rolland, Tomasz Demkow, Thomas E Hutson, Martin Gore, Scott Freeman, Brian Schwartz, Minghua Shan, Ronit Simantov, Ronald M Bukowski, None, Sorafenib in advanced clear-cell renal-cell carcinoma. The New England Journal of Medicine. ,vol. 356, pp. 125- 134 ,(2007) , 10.1056/NEJMOA060655

J S Waters, C Moss, L Pyle, M James, S Hackett, R A'Hern, M Gore, T Eisen, Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma British Journal of Cancer. ,vol. 91, pp. 1763- 1768 ,(2004) , 10.1038/SJ.BJC.6602209

Jennifer Bacik, Tania Mariani, Paul Russo, Madhu Mazumdar, Victor Reuter, Robert J. Motzer, Treatment Outcome and Survival Associated With Metastatic Renal Cell Carcinoma of Non–Clear-Cell Histology Journal of Clinical Oncology. ,vol. 20, pp. 2376- 2381 ,(2002) , 10.1200/JCO.2002.11.123

Douglas J. Schwartzentruber, Patrick Hwu, Claudia A. Seipp, Linda Rogers-Freezer, Kathleen E. Morton, Donald E. White, David J. Liewehr, Maria J. Merino, Steven A. Rosenberg, James C. Yang, Richard M. Sherry, Seth M. Steinberg, Suzanne L. Topalian, Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer Journal of Clinical Oncology. ,vol. 21, pp. 3127- 3132 ,(2003) , 10.1200/JCO.2003.02.122

Robert J. Motzer, Jennifer Bacik, Lawrence H. Schwartz, Victor Reuter, Paul Russo, Stephanie Marion, Madhu Mazumdar, Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma Journal of Clinical Oncology. ,vol. 22, pp. 454- 463 ,(2004) , 10.1200/JCO.2004.06.132

Dirk Strumberg, Heike Richly, Ralf A. Hilger, Norbert Schleucher, Sonke Korfee, Mitra Tewes, Markus Faghih, Erich Brendel, Dimitris Voliotis, Claus G. Haase, Brian Schwartz, Ahmad Awada, Rudolf Voigtmann, Max E. Scheulen, Siegfried Seeber, Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors Journal of Clinical Oncology. ,vol. 23, pp. 965- 972 ,(2005) , 10.1200/JCO.2005.06.124

Scott M. Wilhelm, Christopher Carter, LiYa Tang, Dean Wilkie, Angela McNabola, Hong Rong, Charles Chen, Xiaomei Zhang, Patrick Vincent, Mark McHugh, Yichen Cao, Jaleel Shujath, Susan Gawlak, Deepa Eveleigh, Bruce Rowley, Li Liu, Lila Adnane, Mark Lynch, Daniel Auclair, Ian Taylor, Rich Gedrich, Andrei Voznesensky, Bernd Riedl, Leonard E. Post, Gideon Bollag, Pamela A. Trail, BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis Cancer Research. ,vol. 64, pp. 7099- 7109 ,(2004) , 10.1158/0008-5472.CAN-04-1443

Mark J. Ratain, Tim Eisen, Walter M. Stadler, Keith T. Flaherty, Stan B. Kaye, Gary L. Rosner, Martin Gore, Apurva A. Desai, Amita Patnaik, Henry Q. Xiong, Eric Rowinsky, James L. Abbruzzese, Chenghua Xia, Ronit Simantov, Brian Schwartz, Peter J. O'Dwyer, Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Journal of Clinical Oncology. ,vol. 24, pp. 2505- 2512 ,(2006) , 10.1200/JCO.2005.03.6723

Francesca Carlomagno, Suresh Anaganti, Teresa Guida, Giuliana Salvatore, Giancarlo Troncone, Scott M. Wilhelm, Massimo Santoro, BAY 43-9006 Inhibition of Oncogenic RET Mutants Journal of the National Cancer Institute. ,vol. 98, pp. 326- 334 ,(2006) , 10.1093/JNCI/DJJ069